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Abstract
Background: Methyl-CpG binding domain protein 1 (MBD1), a suppressor of gene transcription,
may be involved in inactivation of tumor suppressor genes during tumorigenesis. Over-expression
of MBD1 has been reported in human pancreatic carcinomas.
Methods: In this study, we established a MBD1-knock-down pancreatic cancer cell line (BxPC-3)
using stable RNA interference, to compare the proteomic changes between control and MBD1-
knock-down cells using two-dimensional gel electrophoresis and mass spectrometry.
Results: We identified five proteins that were up-regulated and nine proteins that were down-
regulated. Most of the identified proteins are involved in tumorigenesis, some are prognostic
biomarkers for human malignant tumors.
Conclusion: Our data suggest that these differential proteins may be associated with the function
of MBD1, and provide some insight into the functional mechanism of MBD1 in the development of
pancreatic cancer.
Background
The incidence rate of pancreatic cancer has increased sig-
nificantly in recent years. Recent studies examining the
origin of pancreatic cancer have revealed that molecular
alterations, including changes in tumor suppressor genes
and oncogenes involved in multiple cellular signaling
pathways, may have a significant role in the multistage
carcinogenesis of pancreatic cancer [1].
DNA methylation at CpG islands is the major epigenetic
modification of mammalian genomes and is required for
gene regulation and genome stability [2]. Aberrant DNA
methylation, especially the hypermethylation of tumor
suppressor genes, has been reported to be associated with
the inactivation of tumor suppressor genes and tumori-
genesis [3]. Methyl-CpG binding domain protein 1
(MBD1) is a mammalian protein that binds methylated
CpG islands symmetrically and couples DNA methylation
to transcriptional repression [4]. This biological property
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pressor genes that may contribute to tumorigenesis [4,5].
We have previously reported that MBD1 is over-expressed
in human pancreatic carcinomas and that over-expression
of MBD1 correlated significantly with lymph node metas-
tasis [6]. However, the role of MBD1 in the development
of pancreatic cancer is still unknown.
In this study, we silenced MBD1 expression in the pancre-
atic cancer cell line BxPC-3 using the RNA interference
(RNAi) technique. We used two-dimensional gel electro-
phoresis (2-DE) to detect differential protein expression
in the BxPC-3/MBD1-siRNA and control BxPC-3/vector
cell lines. The differential expression patterns between the
two cell lines were identified by matrix-assisted laser des-
orption/ionization time-of-flight mass spectrometry
(MALDI-TOF-MS). Our data provide some insight into
the functional mechanism of MBD1 in the development
of pancreatic cancer.
Methods
Cell lines and culture
The human pancreatic cancer cell line, BxPC-3, was pur-
chased from Shanghai Institutes for Biological Science
(China). Cells were cultured in RPMI-1640 media (Gibco
BRL, USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco BRL, USA) in a 37°C incubator with 5%
CO2.
Construction of the recombinant MBD1-siRNA plasmid
The design of two double stranded siRNA oligonucle-
otides targeting MBD1 was based on the published
sequence of MBD1 (BC033242). BamH I and Hind III rec-
ognition sequences were added as indicated below. The
MBD1 target 1 sequence was 5'- GCATCTGGCCCAG-
GAATTA -3'. The forward oligonucleotide sequence was:
5'...GATCCCGCATCTGGCCCAGGAATTAttcaagagaTAAT-
TCCTGGGCCAGATGC TTTTTTGGAAA ...3' and the
reverse sequence was: 5'...AGCTTTTCCAAAAAA GCATCT-
GGCCCAGGAATTA tctcttgaaTAATTCCTGGGCCAGATGC
GG ...3'. The MBD1 target 2 sequence was 5'- CCAAGAG-
GATTGTGGCCAT -3'. The forward oligonucleotide
sequence was: 5'...GATCCCCCAAGAGGATTGT-
GGCCATttcaagaga ATGGCCACAATCCTCTTGG TT TTTT-
GGAAA ...3', the reverse sequence was:
5'...AGCTTTTCCAAAAAACCAAGAGGATTGTGGCCAT-
tctcttgaaATGGCCACAATCCTCTTGGGG ...3'. The oligo-
nucleotides were annealed in a buffer (100 mmol/L
potassium acetate, 30 mmol/L HEPES-KOH pH 7.4, and 2
mmol/L Mg-acetate) and incubated at 95°C for 4 min-
utes, slow cooling to room temperature for 1 hour. The
restriction endonucleases BamH I and Hind III were used
to linearize the PGCsi-U6/Neo/GFP vector (kindly pro-
vided by Professor Huang Weida, Department of Bio-
chemistry, Fudan University). The annealed double
stranded oligonucleotides were ligated into the BamH I
and Hind III sites of the linear pGCsi-U6/Neo/GFP vector
using T4 DNA ligase. The plasmid was then transformed
and recombinant plasmid DNA was extracted for DNA
sequencing.
Stable transfection
The targeting and control vectors were transfected into
BxPC-3 cells using Lipofectamine 2000 (Invitrogen, USA).
Briefly, BxPC-3 (80–90% confluence), were subcultured
into 6-well plates (1 × 106 cells/well) at 37°C in a humid-
ified atmosphere of 5% CO2 for 24 hours. The diluted
plasmid and liposome were incubated in serum and anti-
biotics-free DMEM for 5–10 minutes then added to the
cell culture plates. The transfected cells were cultured for 5
hours then transferred to fresh media containing 10%
FBS. G418 was used to select the positive clones. BxPC-3
cells stably transfected with the MBD1-siRNA plasmid
were named "BxPC-3/MBD1-siRNA". Control BxPC-3
cells transfected with vector alone were named "BxPC-3/
vector".
Western blot analysis
The total cell lysate was separated on a 10% sodium
dodecyl sulfate-polyacrylamide gel using electrophoresis
(SDS-PAGE) and transferred onto a polyvinylidene diflu-
oride(PVDF) membranes. The membrane was blocked for
1 hour at room temperature in 10% FBS, then incubated
overnight at 4°C with different primary antibodies (anti-
MBD1, USBiological, USA, 1:250; anti-vimentin, Santa
Cruz, USA, 1:250; anti-stathmin, Cell Signaling Technol-
ogy, USA, 1:250;anti-hnRNP K Santa Cruz, USA, 1:500;
anti-GRP78, BD Pharmingen, USA, 1:300; anti-HSP70,
BD Pharmingen, USA, 1:300; anti-tubulin beta2, Novo-
castra, UK,1:50). After washing three times, the mem-
brane was incubated with secondary antibody for 1 hour
at room temperature. The signal was detected by the ECL
detection system (Chemicon, USA)
Real-time quantitative RT-PCR
Total RNA was extracted from the BxPC-3/MBD1-siRNA
and BxPC-3/vector cells using Trizol reagent (Gibco BRL,
USA). First-strand cDNA was synthesized from 1 µg total
RNA using RevertAid™ M-MuLV Reverse Transcriptase
(Fermentas, USA) according to the manufacturer's instruc-
tions. Quantitative RT-PCR was performed on an ABI
PRISM 7300 system using SYBR Green PCR Master Mix
(Takara, Japan). Primer sequences and annealing temper-
ature for MBD1, vimentin and GRP78 were shown in
Table 1. β-actin was used as an endogenous control.
Quantification results were expressed in terms of the cycle
threshold (CT) value. The comparative CT method [7] was
used to quantify relative MBD1, vimentin and GRP78
expression. Briefly, the CT values were averaged for eachPage 2 of 10
(page number not for citation purposes)
BMC Cancer 2008, 8:121 http://www.biomedcentral.com/1471-2407/8/121triplicate. Differences between the mean CT values of
MBD1, vimentin, GRP78 and those of β-actin were calcu-
lated as delta CT = CT (target gene) -CT (β-actin). Final
results, expressed as N-fold differences of gene expression
between BxPC-3/MBD1-siRNA and control BxPC-3 cells,
were determined as 2-delta delta CT (delta delta CT = delta CT
BxPC-3/MBD1-siRNA – delta CT control BxPC-3).
2-D gel electrophoresis
BxPC-3/MBD1-siRNA and BxPC-3/vector cells were har-
vested, and lysed in lysis buffer (7 M urea, 2 M thiourea,
65 mM DTT, 4% Chaps, 40 mM Tris, 2% Pharmalyte).
After incubation at 37°C for 1 hour, the lysates were cen-
trifuged at 15000 rpm for 30 minutes at 4°C. The concen-
tration of the total protein in the supernatant was
determined using the Bradford method. Protein samples
were diluted to 350 µl with rehydration solution (7 M
urea, 2 M thiourea, 15 mM DTT, 0.5% IPG (immobilized
pH gradient) buffer, and trace bromophenol blue) and
applied to IPG strips (pH 4–7, Amersham Biosciences,
Sweden) for 12 hours. Isoelectric focusing (IEF) was per-
formed on an Ettan IPGphor (Amersham Biosciences).
Focused IPG strips were equilibrated for 15 minutes in a
solution (6 M urea, 2% SDS, 30% glycerol, 50 mM Tris-
HCl, pH 8.8 and 1% DTT), followed by 15 minutes in the
same solution containing 2.5% iodoacetamide instead of
1% DTT. Equilibrated strips were placed on 10% acryla-
mide gels containing SDS. SDS-PAGE was performed on a
PROTEAN II system (Bio-Rad, USA). After electrophore-
sis, silver staining was performed as described previously
[8].
Image scanning and analysis
The stained 2-DE gels were scanned using a GS-800 Imag-
escanner (Bio-Rad), and analyzed using ImageMaster 2D
software (Amersham Biosciences). Three separate gels
with the fewest artifacts were prepared for each cell line
and selected for statistical analysis. The criterion for a dif-
ferential expression of any particular protein between the
two cell lines was set as at least a 3-fold change in spot
intensity according to a previous study [9].
Protein identification by MALDI-TOF-MS
The protein spots were excised using an Ettan spot picker
(Amersham Biosciences) and digested with trypsin.
Briefly, silver-stained protein spots were destained with 15
mM potassium ferricyanide and 50 mM sodium thiosul-
fate (1:1) and washed with Millipore-Q water. The gel
pieces were dehydrated with acetonitrile, dried in a vac-
uum centrifuge, and incubated in 20 µl of digestion solu-
tion containing 20 mM ammonium bicarbonate and 20
ng/µl sequencing grade trypsin (Promega, USA). After the
tryptic digestion at 37°C for at least 3 hours, the resultant
peptides were extracted (50 µl of 50% acetonitrile),
desalted with ZipTip C18 columns (Millipore Corp, USA),
and eluted with 2.5 µl of 50% acetonitrile containing
0.5% TFA (Triflouroacetic acid) and 3 mg/ml α-cyano-4-
hydroxycinnamic acid. Samples were spotted onto stain-
less steel MALDI sample target plates, and analyzed by
4700 Proteomics Analyzer MALDI-TOF/TOF mass spec-
trometer (Applied Biosystems, USA) in the positive ion
reflector mode. Peptide matching and a protein search
against the NCBI databases were performed using the
Mascot search engine.
Statistical analysis
Student's t test was used to compare the difference
between mean values. P < 0.05 was considered to be sta-
tistically significant. All statistical calculations were per-
formed using the SPSS11.5 statistical software package.
Results
Establishing stable MBD1-knock-down pancreatic 
carcinoma cell lines
The siRNA sequences targeting MBD1 were successfully
cloned into the pGCsi-U6/Neo/GFP plasmid. DNA
sequencing was performed to confirm that the recom-
binant plasmid was constructed correctly (data not
shown). The plasmid expressed green fluorescent protein
(GFP) to allow observation of the transfected cells by flu-
orescent microscopy. Twenty-four hours after transfec-
tion, transfected BxPC-3 cells expressed GFP. Cells were
selected with G418 (800 µg/mL) for approximately three
weeks: positive cell clones were identified by fluorescent
microscopy (Fig 1). Western blot analysis revealed that
the expression of MBD1 in BxPC-3/MBD1-siRNA cells
was significantly lower than in BxPC-3/vector and
untreated BxPC-3 cells (Fig 2A). Quantitative RT-PCR con-
firmed that MBD1 in BxPC-3/MBD1-siRNA cells was
Table 1: Quantitative RT-PCR primer sequences, amplicon length and annealing temperature
Gene Primer sequences Amplicon length Annealing temperature
MBD-1 5' TCTGGTTGCCAAGGTCCAAA 3'
5' ACATCCATCTTCCCTTCCCGA 3'
122bp 61°C
vimentin 5' TGGAAGAGAACTTTGCCGTTG 3'
5' AAGGTGACGAGCCATTTCCTC 3'
101bp 60°C
GRP78 5' CACCAATGACCAGAATCGCCT 3'
5' CAATGCGCTCCTTGAGCTTT 3'
101bp 60°CPage 3 of 10
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5A).
2-DE analysis and differential expression of proteins
To investigate the changes in protein expression in pancre-
atic cancer after MBD1 knock-down, we performed a com-
parative proteomic study between BxPC-3/MBD1-siRNA
and BxPC-3/vector cell lines. Fig 3 shows two representa-
tive 2-DE maps from BxPC-3/MBD1-siRNA and BxPC-3/
vector cell lines in the pH range 4–7. Among the spots
investigated, almost 30 proteins were differential
expressed. But some of them were unknown proteins that
could not be identified, and some of them with different
PI and MW finally proved to be the same protein (such as
348 and 429, both identified as tubulin beta), which sug-
gest different post-translational modification. Finally, 14
spots were identified as differentially expressed proteins
between the BxPC-3/MBD1-siRNA and BxPC-3/vector cell
lines. Using image analysis we found that five spots (429,
896, 384, 922, 363) were up-regulated and nine spots
(391, 1177, 1264, 640, 557, 703, 649, 1023, 218) were
down-regulated after the silencing of MBD1 using RNAi
(Fig 4).
Identification of differentially expressed proteins by 
MALDI-TOF-MS
The 14 differentially expressed protein spots were ana-
lyzed by MALDI-TOF-MS and identified by Mascot search.
As shown in Table 2, the following five proteins were up-
regulated: i) tubulin beta 2, ii) splicing factor arginine/ser-
ine-rich isoform 1, iii) ER-60 protease, iv) propyl 4-
hydroxylase, beta subunit precursor (P4 hb) and v) EF
hand domain family, member D2. The following nine
proteins were down-regulated: i) 78 kDa glucose-regu-
Stable transfection of the MBD1-siRNA recombinant plasmid in BxPC-3 cellsFigure 1
Stable transfection of the MBD1-siRNA recombinant plasmid in BxPC-3 cells. A, B: Transfected cells 24–72 hours 
after transfection. C, D: Positive cell clones 3–4 weeks after transfection.Page 4 of 10
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Detection of MBD1 and differentially expressed proteins by Western blot analysisFigure 2
Detection of MBD1 and differentially expressed proteins by Western blot analysis. The lanes are as follows: left: 
BxPC-3/vector; middle: untreated BxPC-3; right: BxPC-3/MBD1-siRNA. A: MBD1: 70 kDa, B: stathmin: 19 kDa, C: tubulin 
beta2: 53 kDa, D: vimentin: 57 kDa, E: HSP A8: 70 kDa, F: GRP78: 78 kDa, G: hnRNP K: 65 kDa, H: β-actin: 42 kDa.
Table 2: Proteins that showed differential expression after RNAi targeting MBD1
Spot No. Accession No. Protein Name Protein MW Protein pI Protein Score Fold change
429 gi| 5174735 tubulin, beta, 2 49808 4.79 68 ↑4.05
896 gi| 5902076 splicing factor, arginine/serine-rich 1 
isoform 1
27727.8 10.37 191 ↑3.52
384 gi| 1208427 ER-60 protease 56760.8 5.98 140 ↑4.09
363 gi| 20070125 prolyl 4-hydroxylase, beta subunit 
precursor
57058.6 4.76 70 ↑4.06
922 gi| 20149675 EF hand domain family, member D2 26680.5 5.15 120 Only in BxPC-3/MBD1-siRNA
218 gi| 14916999 78 kDa glucose-regulated protein 
precursor (GRP 78) (Heat shock 70 kDa 
protein 5)
72377.5 5.07 249 ↓4.02
1023 gi| 6048243 TOLLIP protein 23206.7 5.68 116 Only in BxPC-3/ vector
649 gi| 48257068 HSPA8 protein 64633.1 5.36 95 Only in BxPC-3/ vector
391 gi| 62414289 vimentin 53619.1 5.06 334 ↓20.64
1177 gi| 5031851 stathmin 1 17291.9 5.76 90 ↓3.48
1264 gi| 14719392 cofilin2 18724.8 7.66 74 Only in BxPC-3/ vector
640 gi| 55958543 heterogeneous nuclear ribonucleoprotein 
K
33954.7 5.54 74 Only in BxPC-3/ vector
557 gi| 4503519 eukaryotic translation initiation factor 3, 
subunit 5
37540.1 5.24 131 Only in BxPC-3/ vector
703 gi| 141623 Zinc finger protein ZFP-36 66639.8 8.99 65 Only in BxPC-3/ vector
BMC Cancer 2008, 8:121 http://www.biomedcentral.com/1471-2407/8/121lated protein precursor (GRP 78), ii) Tollip (toll interact-
ing protein), iii) heat shock 70 kDa protein 8 (HSP A8),
iv) vimentin, v) stathmin 1, vi) cofilin 2, vii) heterogene-
ous nuclear ribonucleoprotein K (hnRNP K), viii) eukary-
otic translation initiation factor 3 (eIF3), subunit 5, and
ix) zinc finger protein ZFP-36.
2-DE maps from BxPC-3/MBD1-siRNA (left) and BxPC-3/vector (right) cell linesFigure 3
2-DE maps from BxPC-3/MBD1-siRNA (left) and BxPC-3/vector (right) cell lines. Figure shows two representative 
2-DE maps in the pH range 4–7. 2-DE of each cell line was repeated at least three times.
Comparison of differentially expressed proteins between BxPC-3/MBD1-siRNA and BxPC-3/vector cell linesFigure 4
Comparison of differentially expressed proteins between BxPC-3/MBD1-siRNA and BxPC-3/vector cell lines. 
A, B, C, D, E: five areas of labeled protein spots on 2-DE gel. left panel: BxPC-3/MBD1-siRNA, right panel: BxPC-3/vector.Page 6 of 10
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To verify the authenticity and reproducibility of the pro-
teomics results, vimentin, stathmin, hnRNP K, GRP78,
HSP A8 and tubulin beta2 were selected and confirmed by
Western blot. As shown in Fig. 2, vimentin, stathmin,
hnRNP K, GRP78 and HSP A8 were significantly down-
regulated after MBD1 knock-down, while tubulin beta2
was up-regulated in BxPC-3/MBD1-siRNA, which were
consistent with proteomics analyses.
In a short term RNAi experiment (two siRNA used), we
found that 48 hours after MBD1-siRNA vector transfec-
tion, the mRNA level of vimentin and GRP78 were down-
regulated about 9.23-fold and 7.14-fold respectively by a
quantitative RT-PCR assay (Fig 5B,C), which indicated
that the changes in protein expression could be secondary
to changes in cells caused by MBD1 knock-down.
Discussion
MBD1 is a mammalian protein that binds symmetrically
methylated CpG sequences and regulates gene expression
in association with DNA methylation [2]. A powerful
transcriptional repression domain (TRD) at the C termi-
nus of MBD1 can actively repress transcription at a dis-
tance [4]. Thus, MBD1 may have an important role in the
silencing of tumor suppressor genes that are hypermethyl-
ated at their promoter CpG islands in cancer cells [5,10].
Previously, we have shown that the gene expression of
MBD1 is significantly increased in pancreatic carcinomas
compared to normal pancreatic tissue, with a simultane-
ous decrease in the expression of some tumor suppressor
genes (CDH1, RB) [11]. We also found that the protein
and mRNA expressions of MBD1 in pancreatic carcinoma
were significantly higher than in normal tissues. Further-
more, the expression of MBD1 correlated with lymph
node metastasis [6]. However, the role of MBD1 during
the development of pancreatic cancer is still unknown.
The present study combined a proteomic approach with
RNAi technology to identify proteins associated with
MBD1 function in pancreatic cancer. We successfully used
RNAi technology to construct a recombinant MBD1-
siRNA plasmid that stably knocked-down MBD1 gene
expression in the BxPC-3 human pancreatic cancer cell
line. We identified 14 differentially expressed protein
spots between the two cell lines using MALDI-TOF-MS.
MBD1 affect gene expression according to the status of
DNA methylation. Fujita N et al indicated that MBD1 acts
as a transcriptional regulator depending on the density of
methyl-CpG pairs through the cooperation of MBD,
CXXC, and TRD sequences. MBD1v1 represses transcrip-
tion preferentially from both unmethylated and sparsely
methylated promoters, while MBD1v3 inhibits densely
methylated but not unmethylated promoter activities.
Moreover, they also found that MBD1 enhanced tran-
scription from the some methylated promoter [2]. In our
study, 9/14 proteins were downregulated and 5/14 pro-
teins were upregulated after MBD1 knock-down, maybe
related with different transcriptional regulation way of
MBD1.
Among the 14 MBD1-associated proteins identified in
this study, vimentin was found to be down-regulated 20-
fold in the BxPC-3/MBD1-siRNA cell line compared to the
control BxPC-3/vector cell. Vimentin, a major intermedi-
ate filament protein of mesenchymal cells, was found to
be over-expressed in some human cancer tissues and asso-
ciated with prognostic indicators [12,13]. Vimentin exon-
1 sequences are methylated in most of colon cancer tis-
sues and aberrant methylation of vimentin has become a
novel molecular biomarker of colorectal cancer [14]. In
the short term RNAi experiment, the mRNA level of
vimentin was also down-regulated after MBD1 knock-
down, indicated that MBD1 may involve in DNA methyl-
ation of vimentin and mediate the expression of vimentin
in pancreatic cancer.
We also found that several members of the HSP family
(GRP78 and HSP A8) were down-regulated in the absence
of MBD1. GRP78 promotes tumor proliferation, survival,
metastasis, and resistance to a wide variety of therapies
[15,16]. Indeed, it has been shown that cancer cells adapt
to chronic stress in the tumor microenvironment by
inducing the expression of GRP78 [15,16]. Studies show
that Heat shock proteins are methylated in mammalian
cells and HSPs expressions are associated with aberrant
methylation of promoter CpG islands [17-19]. In this
study, the down-regulation of both GRP78 and HSP A8
after MBD1 knock-down, suggest that MBD1 may affect
the expression of HSPs in pancreatic cancer through DNA
methylation.
Many of the proteins that were found to be down-regu-
lated by the knock-down of MBD1 have been shown to be
over-expressed in certain cancers. For example, stathmin,
a microtubule-destabilizing protein, is expressed at high
levels in a wide variety of human cancers [20,21]. Inhibi-
tion of stathmin expression in malignant cells has been
shown to interfere with cell cycle progression and abro-
gates the transformed phenotype [20,21]. hnRNP K,
involved in regulating transcription, mRNA shuttling,
RNA editing and translation, has been reported to be over-
expressed in several human cancer tissues [22,23]. In
colorectal cancer, patients who presented with hnRNP K-
positive tumors had a poorer survival outcome [22,23].
EIF3 plays an essential role in the rate-limiting initiation
phase of translation, and increased mRNA and protein
levels have been detected in several human tumors. Fur-Page 7 of 10
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Quantitative RT-PCR assayFigure 5
Quantitative RT-PCR assay. A: MBD1 in BxPC-3/MBD1-siRNA cells was downregulated about 14.76-fold after RNAi. B: In 
a short term RNAi experiment (48 hours after MBD1-siRNA vector transfection), vimentin was downregulated about 9.23-
fold. C: In a short term RNAi experiment (48 hours after MBD1-siRNA vector transfection), GRP78 was downregulated about 
7.14-fold.
BMC Cancer 2008, 8:121 http://www.biomedcentral.com/1471-2407/8/121thermore, over-expression of eIF3 is reportedly a prognos-
tic biomarker for poor clinical outcome [24]. Cofilin 2, an
actin-depolymerizing factor that is mainly expressed in
smooth muscle cells of collateral arteries, has been associ-
ated with angiogenesis [25]. Most of these proteins play
an important role in tumorigenesis, some of them are
prognostic biomarkers for human malignant tumors, and
some were involved in methylation. For instance, differ-
ent methylation sites in hnRNP K have been identified
and shown to influence protein-protein interactions [26].
Stathmin also presents aberrant methylation in prostate
cancer cell [27]. Down-regulation of these tumor-related
proteins after MBD1-knock-down suggests that MBD1
may play a significant role in pancreatic cancer through
regulating methylation.
Among the five proteins that were up-regulated, ER-60
protease and P4 hb are multifunctional proteins that
belong to the protein disulfide isomerase family that is a
chaperone protein and related with tumor cell migration
and invasion [28-30]. Tubulin beta2, the subunit protein
of microtubules, is present in the cell nuclei of a variety of
cancers [31]. In colorectal cancer research, methylated
DNA sequence within tubulin was identified [32]. Since
these proteins were up-regulated after knock-down of
MBD1, they might be novel MBD1-associated proteins in
pancreatic cancer.
Conclusion
We established a MBD1 knock-down BxPC-3 pancreatic
cancer cell line using a stable RNAi method. The compar-
ative proteomic approach is a useful strategy of proteom-
ics to analyze and compare the differentially expressed
proteins and identify novel target molecules in unknown
pathways. These differential proteins may be associated
with the function of MBD1, our findings provide some
insight into the functional mechanism of MBD1 in the
development of pancreatic cancer.
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